Neurotech Reports Announces Allan May and Walter Greenleaf, PhD, as Keynote Speakers for the 25th Anniversary Neurotech Leaders Forum

Industry veterans headline a neurotech investment forum set for November 9-10.

What the company is saying

Neurotech Reports is promoting its 25th Anniversary Neurotech Leaders Forum, emphasizing the participation of Allan May, Co-Founder and Chairman at Life Science Angels, and Walter Greenleaf, PhD, a neuroscientist and digital health expert from Stanford, as keynote speakers. The announcement frames the event as a major gathering for investors and entrepreneurs to discuss dealmaking, M&A, exits, and growth forecasts in neurotechnology. The company highlights the event's agenda, which includes neuromodulation, AI-driven brain-computer interfaces, bioelectronic medicine, and wearable neurotech, alongside panels on commercialization and funding. James Cavuoto, Editor and Publisher, positions the speaker lineup as a key draw, while Allan May's remarks underscore ongoing opportunities for startups in the sector. The tone is upbeat, focusing on the event's milestone status and the expertise of its participants. No operational, financial, or project-specific data is presented, and the release is structured to attract attention to the event rather than disclose new business developments.

What the data suggests

The announcement provides concrete details about the event: it will occur on November 9-10, marking the 25th anniversary of the Neurotech Leaders Forum. Allan May brings 30 years of neurotech investment experience, and Walter Greenleaf is identified as a leading academic in virtual reality and digital health. The agenda covers current industry themes but does not specify individual companies, deal volumes, or financial commitments. No attendance figures, sponsorship data, or commercial outcomes are disclosed. The release is informational, not evidentiary—there are no metrics to assess the event's impact on the neurotech sector or any listed company. The only hard facts are the dates, the event's longevity, and the credentials of the keynote speakers.

Analysis

The announcement is a standard event release for the 25th Anniversary Neurotech Leaders Forum, highlighting keynote speakers and agenda topics. The tone is positive, but the language is proportionate to the nature of the event and does not overstate realised progress or future benefits. Most claims are factual (event dates, speakers, agenda), with only minor forward-looking statements about the industry's future and opportunities for startups. There is no mention of capital outlay, operational milestones, or financial impact, and no attempt to frame the event as having immediate or long-term financial benefits for any company. The gap between narrative and evidence is minimal, as the claims are limited to event logistics and speaker credentials. No exaggerated or promotional language is used regarding investment outcomes or industry transformation.

Risk flags

• ●There is no disclosure of specific investment commitments, deals, or measurable outcomes tied to the event, so the practical impact for investors remains uncertain. This limits the ability to assess whether the forum will generate actionable value.
• ●The announcement relies on the reputations of high-profile speakers to attract interest, but personal participation does not ensure institutional investment or sector growth. The presence of industry veterans signals credibility but does not substitute for tangible results.
• ●No operational or financial data is provided, making it impossible to gauge the scale, reach, or effectiveness of the event in advancing neurotech commercialization or investment activity.

Bottom line

This announcement is a standard event promotion for the Neurotech Leaders Forum, highlighting respected figures like Allan May and Walter Greenleaf as keynote speakers. While the event may facilitate networking and sector discussion, there is no evidence of direct financial or operational impact for investors. The lack of disclosed outcomes, attendance, or dealflow means the practical significance is limited to industry visibility and potential relationship-building. Investors should treat this as a sector pulse check rather than a catalyst for immediate value. The most important takeaway is that the forum gathers influential voices, but its real-world impact will only be clear after the event and is not substantiated here.

Announcement summary

Neurotech Reports announced that Allan May, Co-Founder and Chairman of the Board at Life Science Angels, and Walter Greenleaf, PhD, Neuroscientist, Virtual Reality, and Digital Health Expert at Stanford University's Virtual Human Interaction Lab, will serve as keynote speakers at the 25th Anniversary Neurotech Leaders Forum. The event will take place on November 9-10 in South San Francisco, CA. The Neurotech Leaders Forum is designed to connect investors and entrepreneurs in the neurotechnology sector to discuss dealmaking, the current state of the market, M&A activity, exits, and both short- and long-term growth forecasts for the industry. Attendees will have the opportunity to engage in candid conversations about investment attraction, commercialization strategies, and the latest perspectives on compliance and regulation. James Cavuoto, Editor and Publisher of Neurotech Reports, commented that the addition of these keynote speakers completes a distinguished lineup for the 25th Anniversary meeting. Allan May, as a keynote speaker, reflected on his 30 years of investing in neurotech, noting the ongoing emergence of new opportunities for startups in the field. The agenda for this year's event includes topics such as neuromodulation, AI-driven brain-computer interfaces (BCIs), bioelectronic medicine, and wearable neurotech. Additional agenda items feature market insights and funding forecasts from investors, as well as panels with entrepreneurs from companies aiming to scale and commercialize neurotechnology solutions. The complete agenda and speaker information are available at www.NeurotechReports.com/LeadersForum. The event is produced by Neurotech Reports, which is part of Cambridge Innovation Institute. Neurotech Reports provides market research, industry analysis, and business news focused on neurotechnology, neuromodulation, and bioelectronic medicine. The company offers insights into emerging technologies, commercial trends, and investment activity in the global neurotech industry.

Disagree with this article?